Literature DB >> 16479547

Adaptive two-stage designs in phase II clinical trials.

Anindita Banerjee1, Anastasios A Tsiatis.   

Abstract

Two-stage designs have been widely used in phase II clinical trials. Such designs are desirable because they allow a decision to be made on whether a treatment is effective or not after the accumulation of the data at the end of each stage. Optimal fixed two-stage designs, where the sample size at each stage is fixed in advance, were proposed by Simon when the primary outcome is a binary response. This paper proposes an adaptive two-stage design which allows the sample size at the second stage to depend on the results at the first stage. Using a Bayesian decision-theoretic construct, we derive optimal adaptive two-stage designs; the optimality criterion being minimum expected sample size under the null hypothesis. Comparisons are made between Simon's two-stage fixed design and the new design with respect to this optimality criterion. Copyright 2006 John Wiley & Sons, Ltd.

Mesh:

Year:  2006        PMID: 16479547     DOI: 10.1002/sim.2501

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

Review 1.  Designing clinical trials for dystonia.

Authors:  Wendy R Galpern; Christopher S Coffey; Alberto Albanese; Ken Cheung; Cynthia L Comella; Dixie J Ecklund; Stanley Fahn; Joseph Jankovic; Karl Kieburtz; Anthony E Lang; Michael P McDermott; Jeremy M Shefner; Jan K Teller; John L P Thompson; Sharon D Yeatts; H A Jinnah
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Optimal Tests of Treatment Effects for the Overall Population and Two Subpopulations in Randomized Trials, using Sparse Linear Programming.

Authors:  Michael Rosenblum; Han Liu; En-Hsu Yen
Journal:  J Am Stat Assoc       Date:  2014-01-01       Impact factor: 5.033

3.  Sequential design of phase II-III cancer trials.

Authors:  Tze Leung Lai; Philip W Lavori; Mei-Chiung Shih
Journal:  Stat Med       Date:  2012-03-16       Impact factor: 2.373

Review 4.  Clinical trial design in non-invasive brain stimulation psychiatric research.

Authors:  André Russowsky Brunoni; Felipe Fregni
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

5.  Proper inference from Simon's two-stage designs.

Authors:  Tatsuki Koyama; Heidi Chen
Journal:  Stat Med       Date:  2008-07-20       Impact factor: 2.373

6.  Boundary problem in Simon's two-stage clinical trial designs.

Authors:  Guogen Shan; John J Chen; Changxing Ma
Journal:  J Biopharm Stat       Date:  2016-02-16       Impact factor: 1.051

7.  Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Authors:  Anne M Noonan; Kristen P Bunch; Jin-Qiu Chen; Michelle A Herrmann; Jung-Min Lee; Elise C Kohn; Ciara C O'Sullivan; Elizabeth Jordan; Nicole Houston; Naoko Takebe; Robert J Kinders; Liang Cao; Cody J Peer; W Douglas Figg; Christina M Annunziata
Journal:  Cancer       Date:  2015-11-13       Impact factor: 6.860

8.  Optimal adaptive two-stage designs for early phase II clinical trials.

Authors:  Guogen Shan; Gregory E Wilding; Alan D Hutson; Shawn Gerstenberger
Journal:  Stat Med       Date:  2015-11-03       Impact factor: 2.373

9.  A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.

Authors:  Jian Wang; Junsheng Ma; Chunyan Cai; Naval Daver; Jing Ning
Journal:  Stat Med       Date:  2021-06-07       Impact factor: 2.497

10.  What inference for two-stage phase II trials?

Authors:  Raphaël Porcher; Kristell Desseaux
Journal:  BMC Med Res Methodol       Date:  2012-08-06       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.